Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child

Casper K Lumby; Lei Zhao; Macarena Oporto; Tim Best; Helena Tutill; Divya Shah; Paul Veys; Rachel Williams; Austen Worth; Christopher J R Illingworth; Judy Breuer

doi:10.1093/cid/ciaa023

Favipiravir and Zanamivir Cleared Infection with Influenza B in a Severely Immunocompromised Child

Clin Infect Dis. 2020 Oct 23;71(7):e191-e194. doi: 10.1093/cid/ciaa023.

Authors

Casper K Lumby¹, Lei Zhao¹, Macarena Oporto², Tim Best², Helena Tutill³, Divya Shah³, Paul Veys², Rachel Williams³, Austen Worth², Christopher J R Illingworth^{1

4}, Judy Breuer^{2

3}

Affiliations

¹ Department of Genetics, University of Cambridge, Cambridge, UK.
² Great Ormond Street Hospital, London, UK.
³ Division of Infection and Immunity, University College London, London, UK.
⁴ Department of Applied Mathematics and Theoretical Physics, University of Cambridge, Cambridge.

PMID: 32124919
DOI: 10.1093/cid/ciaa023

Abstract

A combination of favipiravir and zanamivir successfully cleared influenza B infection in a child who had undergone bone marrow transplant for X-linked severe combined immunodeficiency, with no recovery of T lymphocytes. Deep sequencing of viral samples illuminated the within-host dynamics of infection, demonstrating the effectiveness of favipiravir in this case.

Keywords: favipiravir; genome sequencing; influenza; zanamivir.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Amides
Antiviral Agents / therapeutic use
Child
Humans
Influenza, Human* / drug therapy
Pyrazines / therapeutic use
Zanamivir* / therapeutic use

Substances

Amides
Antiviral Agents
Pyrazines
favipiravir
Zanamivir

Abstract

Publication types

MeSH terms

Substances

Grants and funding